realizing the "Pennies" are the place to be
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
LOL! It's a single-malt scotch & sure to be under $30, otherwise I'll gladly pay the diff!
Sounds great! I'll have an Aberlour A'bunadh.
Here too!!!
You are kidding, right?
http://www.finance-glossary.com/define/price-earnings-ratio-(PE-ratio)/1161/p/e
Relatively low volume - looks like daytraders are gone until the next run....
IMO, gap
Robo,
Have you had enough fun for one day?
....just wonderin'
I'll have to look into it when I get a chance...thx.
Thanks Rod, it isn't the first time my L2 from TDAmeritrade isn't accurate.
It just showed up on mine.....430,000 sh.
I just bought 425,000 sh 10 minutes ago(at .009), yet on my screen it just shows 5K volume so far today. Curious it doesn't show up, especially since I routed thru Hudson Securities and ETMM's 550,000 ask went down to 125,000. Oh well, not important, I guess...........
Whatever the reasons are for the price action today, I'm not a bit worried! The huge volume reinforces the interest in PCFG and whatever the MM's do, whatever the bashers say, this stock will be going way up soon! When the time comes, I'll sell maybe a third of my holdings and retire on the spot! Thanks PCFG!!!
IMHO,
gap
I'm sure TDA is aware of it, plus I'm maxxed out for now and will just sit tight. It appears life will be very good in the not too distant future!!!
IMO, gap
Is anyone else having trouble with TDAmeritrade level 2?
For newcomers,
Join PCFG Millionaires Club:
http://pcfgmillionaires.info/index.php
Hammer, if I may interject here, your numbers would be valid IF those MM's didn't have other shares for sale that don't show up. For example, NITE may have 200,000 shares @ .057 that don't show up, since they only show their best ask.
IMO,
gap
Lowtrade,
Thanks for stopping by. I enjoy reading your thoughts/opinions/frankness & your charts on PCFG, along with many of the other posters' thoughts and opinions.
back to lurking,
gap
Once again, patience is the key. I'm getting that tingly feeling again......
Watching Level II and noticing the ASK is looking thin.... 2 MM's at .0085 then it jumps up to .0126 for CSTI. I feel any buying pressure will launch this puppy............. IMHO
Thanks Trapper Jim. Got it! YEs, a pretty chart it is! Freeing up some more $$$ as we speak....
Thanks. I don't show it on their Command Center 2.0, where all news usually shows up. hmmmmmmm
I don't see the PR on TDAmeritrade either - a reason why I read these boards.....
Just sign up and add your info. I just did today.
press release
May 16, 2011, 1:14 p.m. EDT
Mikros Systems Corporation Reports Substantial Increases in First-Quarter Revenue and Profits; Quarterly Revenues up 119% and Net Income Remains Positive
PRINCETON, N.J., May 16, 2011 /PRNewswire via COMTEX/ -- Mikros Systems Corporation (OTCBB MKRS) announced its financial results for the quarter ended March 31, 2011.
Highlights for the First Quarter 2011 included:
Revenues for the first quarter 2011 were $1,232,405, an increase of $670,024 or 119% from $562,381 for the first quarter of 2010.
Gross Margin for the first quarter 2011 was $618,486, an increase of $314,324 or 103% from $304,162 for the first quarter of 2010.
Operating Income for the first quarter 2011 was $91,159, a positive increase from a loss of ($115,853) in the first quarter of 2010.
Net Income for the first quarter 2011 was $73,382, a positive increase from a loss of ($109,996) in the first quarter of 2010.
Tom Meaney, Mikros President and CEO, said, "Our current strategy has delivered another profitable quarter. We continue to move forward into new business areas including wireless and autonomous power-buoys, while consistently delivering quality products, such as the Adaptive Diagnostic Electronic Portable Testset (ADEPT) to our current US Navy customers. We are highly confident that our sustained quarterly successes will translate into positive year-end results."
The Company expects to eventually deliver multiple ADEPT systems for use on every US Navy Aegis Cruiser and Destroyer. Marc Dalby, Mikros VP Business Development and Operations, added "We are in discussion with our customer on ways to extend the ADEPT systems for use on other electronic systems, and could see positive direction in this area as well as additional orders shortly. We also continue to develop several SBIR projects with the U.S. Navy for mission-planning applications and autonomous self-powered buoys. When completed, we anticipate that these projects, along with continued ADEPT developments, will generate significant increases in revenues and earnings for Mikros over the next several years."
Additional information regarding the company's financial data may be found in the Company's Quarterly Report on Form 10-Q for the first quarter ended March 31, 2011 filed with the U.S. Securities and Exchange Commission. The Form 10-Q may be accessed at www.sec.gov or at the Company's website at www.mikrossystems.com .
About Mikros
Mikros Systems Corporation is an advanced technology company specializing in the research and development of electronic systems technology primarily for military applications. Classified by the U.S. Department of Defense as a small business, its capabilities include technology management, electronic systems engineering and integration, radar systems engineering, combat/command, control, communications, computers and intelligence systems engineering, and communications engineering. Mikros' primary business is to pursue and obtain contracts from the Department of Homeland Security, U.S. Navy, and other governmental authorities. For more information on Mikros visit: www.mikrossystems.com .
Important Information about Forward-Looking Statements: All statements in this news release other than statements of historical facts are forward-looking statements which contain our current expectations about our future results. Forward-looking statements involve numerous risks and uncertainties. We have attempted to identify any forward-looking statements by using words such as "anticipates," "believes," "could," "expects," "intends," "may," "should" and other similar expressions. Although we believe that the expectations reflected in all of our forward-looking statements are reasonable, we can give no assurance that such expectations will prove to be correct. Such statements are not guarantees of future performance or events and are subject to known and unknown risks and uncertainties that could cause the Company's actual results, events or financial positions to differ materially from those included within the forward-looking statements. Such factors include, but are not limited to, changes in business conditions, a decline or redirection of the U.S. Defense budget, the termination of any contracts with the U.S. Government, changes in our sales strategy and product development plans, changes in the marketplace, continued services of our executive management team, our limited marketing experience, competition between us and other companies seeking SBIR grants, competitive pricing pressures, market acceptance of our products under development, delays in the development of products, statements of assumption underlying any of the foregoing, and other factors disclosed in our annual report on Form 10-K for the year ended December 31, 2010 and other filings with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date made. Except as required by law, we undertake no obligation to disclose any revision to these forward-looking statements.
SOURCE Mikros Systems Corporation
Copyright (C) 2011 PR Newswire. All rights reserved
press release
April 26, 2011, 4:05 p.m. EDT
Provectus Receives Orphan Drug Designation from FDA for the Treatment of Liver Cancer
KNOXVILLE, Tenn., Apr 26, 2011 (BUSINESS WIRE) -- Provectus Pharmaceuticals, Inc. (OTC BB: PVCT, http://www.pvct.com ), a development-stage oncology and dermatology biopharmaceutical company, has received orphan drug designation by the U.S. Food and Drug Administration ("FDA") for Rose Bengal, the active ingredient in its novel oncology drug PV-10, for the treatment of hepatocellular carcinoma ("HCC"), the most common form of primary liver cancer. Provectus completed patient accrual and treatment of all subjects in its Phase 1 clinical trial of PV-10 for liver cancer in January 2011, and is currently designing a Phase 2 study.
Receiving orphan drug designation entitles Provectus to exclusive marketing rights for PV-10 for HCC in the United States for up to seven years if it is the first company to receive marketing approval for this therapeutic drug product. In addition, orphan drug designation allows Provectus to apply for a waiver from the FDA of certain user fees required by the Prescription Drug User Fee Act (PDUFA).
"Receiving orphan drug designation for hepatocellular carcinoma, in combination with our strategy for patent protection of PV-10, is another important step in assuring the value of the company's proprietary property once regulatory approval is achieved," said Dr. Craig Dees, PhD, CEO of Provectus. "Based upon our clinical trials of PV-10 for metastatic melanoma, as well as on the results we are seeing in our Compassionate Use Program for PV-10 for non-visceral cancers, we believe PV-10 will be a safe and effective treatment for many different types of cancers. Preliminary analysis of the results of the Phase 1 liver cancer trial shows that PV-10 should have a role in the treatment of tumors of the liver."
Dr. Dees added, "Orphan drug designation for liver cancer will provide us market exclusivity, as well as financial and regulatory benefits, provided that the trials are completed successfully and the treatment receives FDA approval."
About PV-10
PV-10 is a proprietary, injectable formulation of Rose Bengal, a compound that has been in use for over thirty years by ophthalmologists to assess damage to the eye. It has also been used as an intravenous diagnostic to detect ailments of the liver. Rose Bengal has an established safety history, a short half-life in the bloodstream, and is excreted via the liver and kidneys. Provectus has discovered a novel use for Rose Bengal based on the observation that it is selectively toxic to cancer calls via a process called chemoablation whereby cells undergo a form of cell death that mimics both features of necrosis and apoptosis. Provectus has completed its Phase 2 clinical trial of PV-10 for metastatic melanoma, and is currently in conversation with both the Food and Drug Administration (FDA) regarding the design of a pivotal Phase 3 randomized controlled trial suitable for SPA ("Special Protocol Assessment"), and the Australian Therapeutic Goods Administration to review regulatory approval of PV-10 for melanoma in Australia.
About Provectus Pharmaceuticals, Inc.
Provectus Pharmaceuticals specializes in developing oncology and dermatology therapies. Its novel oncology drug PV-10 is designed to selectively target and destroy cancer cells without harming surrounding healthy tissue, significantly reducing systemic side effects. Its oncology focus is on melanoma, breast cancer and metastatic cancers of the liver. The Company has received orphan drug designations from the FDA for its melanoma and hepatocellular carcinoma indications. Its dermatological drug PH-10 also targets abnormal or diseased cells, with the current focus on psoriasis and atopic dermatitis. Provectus has recently completed its Phase 2 trials of PV-10 as a therapy for metastatic melanoma, and of PH-10 as a topical treatment for atopic dermatitis and psoriasis. Information about these and the Company's other clinical trials can be found at the NIH registry, www.clinicaltrials.gov . For additional information about Provectus please visit the Company's website at www.pvct.com or contact Porter, LeVay & Rose, Inc.
FORWARD-LOOKING STATEMENTS: The forward-looking statements contained herein are subject to certain risks and uncertainties that could cause actual results to differ materially from those reflected in the forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect management's analysis only as of the date hereof. The company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date thereof.
SOURCE: Provectus Pharmaceuticals, Inc.
Provectus Pharmaceuticals, Inc.
Peter R. Culpepper, CFO
866-594-5999 #30
or
Porter, LeVay & Rose, Inc.
Marlon Nurse, DM, VP - Investor Relations
Bill Gordon, SVP - Media Relations
212-564-4700
Copyright Business Wire 2011
On the bottom left is just the mileage legend. The only date is from bottom middle to the right and 2011 is mentioned twice, along with Google & some other stuff - on every map I've looked at. Not a big deal, just not up-to-date at all!
pkp544,
Same here. If I google earth my house, there is a pic of two trees that I cut down at least 5 years ago! It's too bad there isn't a date stamped on it somehow.
gap
Then it may be an issue with your broker, a phone call to them if you want it bad enough, but when that's happened to me, I get them the make the trade and only get a weak apology from them for not executing when they should.....
I'm not surprised the BID didn't move, if the trade hasn't gone thru------is it an AON order? That's one way it won't go thru right away.......
.And two Yoop Pups, I got two of my sons in GRDO too!
I meant, "Are you a yooper too?"
Even without your U.P. map, you sound like a yooper. Hi Neighbor!
Just signed up.....Great Idea!
patiently waiting,
gap
Here comes .025!
Been there, done that too. It's a gamble you have to take, but if you want it bad enough, you either have to put your order in for a higher amount(in which the MM's will be glad to charge you more) using AON, or not using it.
Yes, I'd call TDA too, and clear things up. AON orders are safer so they don't just fill a small amount of the order and you pay commission on a small order. But if you want the stock bad enough, you sometimes have to order it wothout the AON.
Is your order for "All or None"?
No more games? That could just be someone putting in a buy at .0032
That pic makes a great new background on my laptop!
Thx. I've been watching GRDO and thought this is a good time to get in.
ooops, meant for this to be public reply.. That 850,000 was part of my 1 Mil buy
The Trade for Trade seems to be keeping the day-traders out, seeing how low the volume is. IMHO